| Expression pattern: |
DN |
| Associated gene: |
MEF2A |
| Associated microRNA: |
miR-615-3p |
| Biological function: |
Suppresses gefitinib resistance and inhibits NSCLC cell proliferation by arresting the cell cycle, promoting apoptosis, and reducing mitochondrial oxidative phosphorylation. |
| Molecular mechanism: |
Acts as a ceRNA sponge binding miR-615-3p to regulate MEF2A, thereby affecting cell cycle, apoptosis, and mitochondrial OXPHOS; exosomal transfer of circKIF20B modulates recipient cell gefitinib sensitivity. |
| Biological pathway or process: |
cell cycle (inhibits); apoptosis (promotes); oxidative phosphorylation (inhibits); drug resistance (inhibits); ceRNA regulation (other) |
| Detected method: |
Q
S
|
| Validation methods: |
RNA-seq; RT-qPCR; Back-Splice Junction PCR / divergent primers PCR; RNase R Treatment; Actinomycin D / DRB Stability Assay; Sanger Sequencing; FISH / smFISH; Nuclear-Cytoplasmic Fractionation; Luciferase Reporter Assay; RNA Pull-Down; RIP (RNA Immunoprecipitation); Transfection; CCK8; EdU Staining; Cell Cycle Assay; Annexin V/PI Flow Cytometry; Western Blot; In Vivo Animal Model; IHC (Immunohistochemistry); Clinical Sample Validation; Bioinformatics Analysis |
| Clinical significance: |
CircKIF20B was negatively correlated with tumor size and tumor stage; exosomal circKIF20B is expected to be an alternative liquid biopsy candidate and potential therapeutic target in gefitinib-resistant NSCLC. |
| Description: |
CircKIF20B (hsa_circ_0019079) is down-regulated in NSCLC tumor tissues and in serum exosomes from gefitinib-resistant patients. It suppresses proliferation and gefitinib resistance by acting as a ceRNA sponge for miR-615-3p to increase MEF2A, leading to cell-cycle arrest, enhanced apoptosis, and reduced mitochondrial OXPHOS; exosomal delivery of circKIF20B can restore gefitinib sensitivity in recipient cells. |
| Confidence score: |
0.8816 |